Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
Evidence - based guidelines address diagnosis, evaluation, and treatment, including early multidisciplinary care team involvement (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 16, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Pathology, Pharmacy, Radiology, Journal, Source Type: news

ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
FRIDAY, April 16, 2021 -- In new guidelines issued by the American Thyroid Association and published in the March issue of Thyroid, recommendations are presented for the diagnosis, evaluation, and treatment of anaplastic thyroid cancer (ATC). Keith... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2021 Category: Pharmaceuticals Source Type: news

Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine
Forgoing postoperative radioactive iodine in low-risk differentiated thyroid cancer is supported by phase 3 data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

Outcomes in Lymph Node Metastases of Thyroid Cancer Outcomes in Lymph Node Metastases of Thyroid Cancer
Should active surveillance be considered for thyroid cancer patients with cervical lymph node metastases?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Increase in Thyroid Cancer Rates Points to Overscreening Increase in Thyroid Cancer Rates Points to Overscreening
Large but variable increases in rates of papillary thyroid cancer in many countries over the past two decades may point to the"diagnostic pressure" of opportunistic high-sensitivity screening, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

First lab-grown mini-thyroids use patients' own tissue
(International Society for Stem Cell Research) To investigate potential alternative treatment strategies for patients with hypothyroidism, researchers have now for the first time succeeded in generating thyroid mini-organs in the lab. In a new study published in Stem Cell Reports, Robert Coppes and colleagues from the University of Groningen, The Netherlands, used healthy thyroid tissue from patients undergoing surgical removal of the thyroid to grow mini-thyroid organs in a lab which resembled thyroid glands in their structure and protein content. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 10, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, News, Source Type: news

Too Much Light at Night May Raise Odds for Thyroid Cancer
A new study ties an overabundance of nighttime artificial light with an elevated risk of thyroid cancer. (Source: WebMD Health)
Source: WebMD Health - February 10, 2021 Category: Consumer Health News Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
WEDNESDAY, Feb. 10, 2021 -- Though living in a bustling urban area may have its upside, all those nighttime lights could come at a price to your health, new research suggests. The study, published online recently in Cancer, a peer-reviewed journal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 10, 2021 Category: General Medicine Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
Title: Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?Category: Health NewsCreated: 2/10/2021 12:00:00 AMLast Editorial Review: 2/10/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 10, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Artificial Light at Night Tied to Thyroid Cancer Risk
Positive association mainly driven by incidence of papillary thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 8, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Journal, Source Type: news

Artificial Light at Night Tied to Thyroid Cancer Risk
MONDAY, Feb. 8, 2021 -- Exposure to artificial light at night (LAN) is positively associated with thyroid cancer risk, according to a study published online Feb. 8 in Cancer. Dong Zhang, Ph.D., from the University of Arkansas for Medical Sciences... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 8, 2021 Category: Pharmaceuticals Source Type: news

Street lamps can increase your risk of thyroid cancer by up to 55%, study shows
Researchers from the University of Texas Health Science Center looked for a link between people developing thyroid cancer and levels of artificial outdoor light. (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2021 Category: Consumer Health News Source Type: news

Study links exposure to nighttime artificial lights with elevated thyroid cancer risk
(Wiley) People living in regions with high levels of outdoor artificial light at night may face a higher risk of developing thyroid cancer. The finding comes from a study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2021 Category: International Medicine & Public Health Source Type: news

Peninsula diagnostics company Veracyte acquires Decipher Biosciences
Genomic diagnostics company Veracyte is continuing to charge hard into the cancer space with a $600 million cash-and-stock acquisition of San Diego precision oncology company Decipher Biosciences Inc. South San Francisco-based Veracyte (NASDAQ: VCVT) offers a number of genomic diagnostics for indications including lung cancer, breast cancer, thyroid cancer and interstitial lung diseases, along with a forthcoming test for lymphoma. The company's combination with Decipher would add genomic test s… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 4, 2021 Category: Health Management Authors: Kevin Truong Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Global Thyroid Cancer Overdiagnosis in Children and Adolescents Global Thyroid Cancer Overdiagnosis in Children and Adolescents
The incidence of thyroid cancer among children and adolescents around the world mimics the patterns in adults, which are attributed to an"epidemic of overdiagnosis."Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Age Group Gets Thyroid Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 26, 2021 Category: General Medicine Source Type: news

Consumer Health: Treating thyroid cancer
Thyroid cancer occurs in the cells of the thyroid, a butterfly-shaped gland located at the base of your neck. Your thyroid produces hormones that regulate your heart rate, blood pressure, body temperature and weight. There may be no signs or symptoms early in the disease. As thyroid cancer grows, it may cause pain and swollen [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 25, 2021 Category: Databases & Libraries Source Type: news

Maternal thyroid disorders may increase thyroid cancer risk in children
Maternal thyroid disorders may be associated with an increased thyroid cancer risk in children, and this risk may remain elevated well into adulthood, according to a study published inThe Lancet Diabetes and Endocrinology.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 21, 2021 Category: Endocrinology Source Type: news

In Utero Exposures May Up Thyroid Cancer Risk in Offspring
WEDNESDAY, Jan. 20, 2021 -- Maternal health and in utero exposures are associated with an increased risk for subsequent thyroid cancer in offspring, according to a study published online Dec. 18 in The Lancet Diabetes& Endocrinology. Cari M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 20, 2021 Category: Pharmaceuticals Source Type: news

What Are the Symptoms of Medullary Thyroid Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 20, 2021 Category: General Medicine Source Type: news

Thyroid cancer screening hits the right note
Researchers from France discovered a thyroid cancer screening technique that...Read more on AuntMinnie.comRelated Reading: Ultrasound: The 60-year-old modality of the future Expanded Medicaid tied to more thyroid cancer diagnoses Doctors order thyroid ultrasounds without good reasons Laryngeal ultrasound helps detect vocal cord polyps Is thyroid cancer overdiagnosed for 9/11 first responders? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 13, 2021 Category: Radiology Source Type: news

New Developments in Thyroid Cancer New Developments in Thyroid Cancer
In this conversation, thyroid cancer experts Drs Megan Haymart and Frank Worden share the latest findings surrounding this increasingly common malignancy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Most Docs Lack Confidence in Using Ultrasound for Thyroid Cancer Surveillance Most Docs Lack Confidence in Using Ultrasound for Thyroid Cancer Surveillance
Just one in five physicians who monitor patients for recurrence of differentiated thyroid cancer (DTC) has high confidence in their ability to use ultrasound for surveillance, new research shows.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 6, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

In-utero exposures associated with increased risk of thyroid cancer
(The University of Bergen) A recent study shows that thyroid cancer is related to in-utero exposures. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Throat cancer symptoms: The most common symptoms of the deadly disease
THROAT cancer is a generic term to describe various types of cancers that affect the area of the throat. It can mean cancer of the thyroid gland, gullet or wind pipe, which have different symptoms. What are they? (Source: Daily Express - Health)
Source: Daily Express - Health - December 19, 2020 Category: Consumer Health News Source Type: news

Thyroid cancer: Do you have a painful lump on your neck? Early sign of the deadly disease
THYROID cancer is a rare type of cancer that affects the thyroid gland. The signs and symptoms are not always obvious until it is too late. A lump which appears on the neck could be a warning sign of the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - December 14, 2020 Category: Consumer Health News Source Type: news

International Study Shows that Active Surveillance Holds Promise as a Treatment Option for Low-Risk Thyroid Cancer
Results from a new study co-led by researchers at Dartmouth’s Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan, show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - December 7, 2020 Category: Hospital Management Authors: Timothy Dean Tags: News Press Release Research The Dartmouth Institute thyroid cancer Source Type: news

Study shows that active surveillance holds promise as a treatment option for low-risk thyroid cancer
(The Geisel School of Medicine at Dartmouth) Results from a new study co-led by researchers at Dartmouth's Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan, show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Thyroid cancer symptoms: Do you have a lump on your neck? How to tell it is cancerous
THYROID cancer is a relatively uncommon type of cancer, with there being around 3,700 new thyroid cancer cases in the UK every year. A lump in the neck is one of the main warning signs - but when should you be worried? (Source: Daily Express - Health)
Source: Daily Express - Health - December 4, 2020 Category: Consumer Health News Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who re quire systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval...
Source: Roche Media News - December 2, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who re quire systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval...
Source: Roche Investor Update - December 2, 2020 Category: Pharmaceuticals Source Type: news

FDA approves pralsetinib for RET-altered thyroid cancers
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
South San Francisco, CA -- December 1, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2020 Category: Drugs & Pharmacology Source Type: news

Sussex research points to new effective breast cancer treatment
(Diamond Light Source) An international five-year study led by scientists at the University of Sussex has provided strong evidence for an effective new target for breast cancer treatment. The study, The structure-function relationship of oncogenic LMTK3 being published in Science Advances, involved researchers from seven institutions across three countries including the UKs Diamond Light Source. It suggests LMTK3 inhibitors could be effectively used for treatment of breast cancer, and potentially other types of cancer such as lung, stomach, thyroid and bladder cancer patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2020 Category: Cancer & Oncology Source Type: news

Follow your Endocrine Networks on Twitter
Each of our eight Endocrine Networks now has its own Twitter account, run by the Convenors. Follow them to share news, events, resources, and to keep up to date with your Network colleagues. Get the conversation going in advance of the Network meetings atSfE BES online!The Endocrine Networks are a platform for collaboration between basic and clinical researchers, clinical endocrinologists and endocrine nurses.Go to theMembers' Area to select and update your preferred Networks.Adrenal and Cardiovascular -@adrenalnetwork Dr Scott MacKenzie& Dr Mick O'Reilly Bone& Calcium -@b...
Source: Society for Endocrinology - November 10, 2020 Category: Endocrinology Source Type: news

Thyroid cancer: Lump, swelling and pain in neck are all warning signs to spot
THYROID cancer survival rates are 84 percent for 10 years or more if diagnosed early. Early diagnosis is crucial therefore and spotting the unusual signs could be a matter of life and death. A sign your thyroid cancer has advanced includes these three signs found on your neck. (Source: Daily Express - Health)
Source: Daily Express - Health - November 10, 2020 Category: Consumer Health News Source Type: news

Who's Going to Manage the Thyroid Cancer? Who's Going to Manage the Thyroid Cancer?
Should primary care physicians have a role in managing thyroid cancer patients who require long-term surveillance ? This commentary explores the issue.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Is Thyroid Cancer Deadly
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2020 Category: General Medicine Source Type: news

Thyroid cancer: Cushing syndrome is a lesser-known warning sign – what is it?
THYROID cancer survival rates are 84 percent for 10 years or more if diagnosed early. Early diagnosis is crucial therefore and spotting the unusual signs could be a matter of life and death. A sign your thyroid cancer has advanced includes Cushing syndrome. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - October 24, 2020 Category: Consumer Health News Source Type: news

Impact of Overweight and Obesity on Thyroid Cancer Incidence Impact of Overweight and Obesity on Thyroid Cancer Incidence
The incidence of papillary thyroid cancer is on the rise in recent years, as is the prevalence of obesity. Is there a connection?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

CMS releases new payment model for radiation oncology
The U.S. Centers for Medicare and Medicaid Services (CMS) today released its...Read more on AuntMinnie.comRelated Reading: Groups tout value of nuclear medicine to Congress Expanded Medicaid tied to more thyroid cancer diagnoses CMS approves payments for Viz.ai software No need to defer cancer treatment for fear of COVID-19 Radiology's declining reimbursement spans over a decade (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

Expanded Medicaid tied to more thyroid cancer diagnoses
Expanded Medicaid coverage was linked to the diagnosis of more thyroid cancer...Read more on AuntMinnie.comRelated Reading: Some cancers found earlier after Medicaid expansion Medicaid expansion tied to early breast cancer diagnosis Medicaid expansion under ACA linked to fewer cancer deaths Is thyroid cancer overdiagnosed for 9/11 first responders? Medicaid expansion boosted cancer screening rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news

Cancer Incidence Up for Adolescents and Young Adults
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 17, 2020 Category: Cancer & Oncology Tags: Dermatology, Endocrinology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Nursing, Oncology, Pediatrics, Journal, Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news